9 results
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
(SLE) Clinical ... Demyelinating Syndrome ... the formation of autoantibodies ... #cerebritis #diagnosis ... #management #treatment
SLE (Systemic Lupus Erythematosus)

Suspect:
Clinical evidence of (fatigue, rash, photosensitivity, inflammatory arthritis, weight loss, and fever) and
Suspect: Clinical ... • Anti-Ro/SSA autoantibodies ... Clinical Features ... pain • Swan neck/Ulnar ... #Diagnosis #Rheumatology
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
lupus erythematosus ... Clinical Presentation ... lupus erythematosus ... #Diagnosis #Management ... #Hematology #Rheumatology
Antinuclear antibodies and Systemic lupus
Anti-dsDNA	60-80%	Association with disease activity (when with Farr assay) and lupus nephritis. Can
-15% If SLE is clinically ... SLE-SSc-AlM overlap syndromes ... #Antinuclear #autoantibodies ... #erythematosus ... #diagnosis #rheumatology
IgG4-Related Disease
Clinical history:  Man, 60 years, multiorgan involvement, unique or multiple inflammatory pseudotumor
4 phenotypes:
 •
Related Disease Clinical ... female, asian • Systemic ... serum lgE, no autoantibodies ... #management #phenotypes ... workup #treatment #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
of autoantibodies ... months to years) Systemic ... Lupus Erythematosus ... comparison #table #rheumatology ... #diagnosis #management
Statin Induced Muscle Toxicity - Summary

Clinical Presentation:
 • Elevations of serum creatine kinase with proximal myalgia
Toxicity - Summary Clinical ... (GBS), systemic ... lupus erythematosus ... (LEMS), systemic ... #management #treatment
Common Variable Immunodeficiency (CVID)

What?
CVID: Immunodeficiency disorder with hypogammaglobulinemia -> increased infection risk secondary to impaired B-cell
may take 6 to 8 ... years Clinical ... hemolytic anemia) • Systemic ... M panel Management ... #diagnosis #management
Anti-NXP-2 Dermatomyositis

What?
DM with generalized subcutaneous edema
Pts have more myalgias, more severe weakness, and an increased prevalence
without these autoantibodies ... erythematous auricular ... papules Clinical ... diagnosed in 7% ... #management #rheumatology